BOSTON, MA--(MARKET WIRE)--Sep 5, 2007 -- Although the number of new cancer drugs entering clinical development more than doubled between the early 1990s and mid-2000s, only eight percent of candidates with known fates won marketing approval in the United States, according to a study recently completed by the Tufts Center for the Study of Drug Development.